Biocryst Pharmaceuticals (BCRX) Return on Invested Capital (2021 - 2026)

Biocryst Pharmaceuticals has reported Return on Invested Capital for 6 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.01%, down 1.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.05% in Q2 2022, with the low at 0.02% in Q1 2022.
• Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.0% in 2024.
• Annual changes were most pronounced in 2022 — Return on Invested Capital grew 9 bps — and 2023, when it slipped 4 bps.
• Biocryst Pharmaceuticals' Return on Invested Capital stood at 0.01% in 2022, then slumped by 76 bps to 0.0% in 2023, then sank by 98 bps to 0.0% in 2024, then plunged by 24295 bps to 0.01% in 2025, then jumped by 186 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.